神经药理学报››2013,Vol. 3››Issue (2): 35-42.
张娜, 窦德强
出版日期:
2013-04-26发布日期:
2014-06-27通讯作者:
窦德强,男,辽宁沈阳人,教授,研究方向:中药化学,Tel:0411-87586014,E-mail:deqiangdou@126.com作者简介:
张娜,女,江苏徐州人,博士研究生,研究方向:中药化学基金资助:
辽宁省高等学校创新团队课题(LT2013020)
ZHANG Na,DOU De-qiang
Online:
2013-04-26Published:
2014-06-27Contact:
窦德强,男,辽宁沈阳人,教授,研究方向:中药化学,Tel:0411-87586014,E-mail:deqiangdou@126.comAbout author:
张娜,女,江苏徐州人,博士研究生,研究方向:中药化学Supported by:
辽宁省高等学校创新团队课题(LT2013020)
摘要:帕金森病(Parkinson's disease,PD)是一种中老年常见的神经系统退行性疾病,PD的主要病理特点是黑质致密部的多巴胺能神经元丢失,进而使纹状体内的多巴胺水平降低。目前,PD的发病原因尚不完全清楚,本文从遗传因素、环境因素、线粒体功能障碍、氧化应激、氮化应激、免疫炎性反应异常、细胞凋亡学说和神经递质失衡等方面系统总结了近年来PD的病理机制,深入了解 PD 发病机制,为PD的进一步研究提供理论依据。
张娜, 窦德强.帕金森病分子病理机制研究进展[J]. 神经药理学报, 2013, 3(2): 35-42.
ZHANG Na,DOU De-qiang.Advances in the Molecular Pathogenesis of Parkinson's Disease[J]. Acta Neuropharmacologica, 2013, 3(2): 35-42.
[1] Paola Paola. Neurodegenerative movement disorders: the contribution of functional imaging[J]. Curr pin in Neuro, 2004, 17(4):459-466. [2] Jan Booij, Remco J J Knol. SPECT imaging of the dopaminergic system in (premo-tor) Parkinson’s disease[J]. Parkinsonism Relat Disord, 2007, 13(13):425-428. [3] Klaus Seppi. MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice[J]. Parkinsonism Relat Disord, 2007; 13(pl3):400-405 [4] Rajput A H, Birdi S. Epidemiology of Parkinson's disease[J]. Parkinsonism & Related Disorders, 1997, 3(4):175-186. [5]Xiromerisiou G, Hadjigeorgiou G M, Gourbali V, et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson’s disease: identification of two novel LRRK2 variants[J]. Eur J Neurol, 2007, 14(1):7–11. [6] Guo Ji-feng, Zhang Xue-wei, Nie Li-luo, et al. Mutation analysis of Parkin, PINK1 and DJ-1 genesin Chinese patients with sporadic early onset parkinsonism[J]. J Neurol, 2010, 257(7): 1170-1175. [7] Peter T Lansbury Jr, Alexis Briee. Geneties of parkinson’s disease and bioehemieal studies of imPlieated gene Produets[J]. Curr Opin Genet Dev, 2002, 12(3):299-306. [8] Rosa M Canet-Aviles, Mark A Wilson, David W Miller, et al. The Parkinson’s disease protein DJ-1 is neruoprotective due to cysteinesulfinic acid-driven mitochondrial localization[J]. Proc Natl Acad Sci USA, 2004, 101(24):9103-9108. [9]Ross O A, Soto A I, Vilarino-Guell C, et al. Genetic variation of Omi/HtrA2 and Parkinson's disease [J]. Disord, 2008, 14(7):539–543. [10] Carola Schiesling,Nicole Kieper,Kay Seidel,et al.Review: familial Parkinson’s disease genetics,clinical phenotype and neuropathology in relation to the common sporadic form of the disease[J]. Neuropathol Appl Neurobiol, 2008, 34(3):255-271. [11] Shinji Higashi, Darren J Moore, Rebecca E Colebrooke. et al. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain[J]. J Neurochem, 2007, 100(2):368–381. [12] Serge Przedborski, Harry Ischiropoulos. Reactive oxygen and nitrogen species: weapons ofneuronal destruction in models of Parkinson's disease[J]. Antioxid Redox Signal, 2005, 7(5-6):685-693. [13] David C Dorman, Anna M Mcelveen, Marianne W Marshall, et al. Tissue manganese concentrations inlactating rats and their offspring following combined in utero and lactation exposure to inhaledmanganese sulfate[J]. Toxicol Sci, 2005, 84(1):12-21. [14] Keiko Imamura, Takao Takeshima, Yoshihiro Kashiwaya, et al. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease[J]. J Neurosci Res, 2006, 84(6):1376-1384. [15] Hiroshi Kawai, Yukiko Makino, Masaaki Hirobe, et al. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism[J]. J Neurochem, 1998, 70(2):745-751. [16] Ravindar R Thomas, Paula M Keeney, James P Bennett. Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex[J]. J Parkinsons Dis, 2012, 2(1):67-76. [17] Laurie H Sanders, J Timothy Greenamyre. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model[J]. Free Radic Biol Med, 2013, 62: 111-120. [18] 黄桂平. 帕金森病的临床研究及展望[J]. 医学综述,2008,14(13):2023-2026. [19] Gail D Zeevalk, Laura P Bernard, William J Nicklas. Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism[J]. J Neurochem, 1998, 70(4): 1421-1430. [20] Vernica Jackson-Lewis, Michael Jakowec, Robert E Burke, et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine [J]. Neurodegeneration, 1995, 4(3): 257-269. [21] 项喜艳. DTT诱发内质网应激-自噬过程中活性氧的作用及其调节机制[D].中国优秀博硕士学位论文全文数据库(硕士):吉林大学,2012. [22] 王虎,蔡定芳.帕金森病与内质网应激[J]. 国际神经病学神经外科学杂志,2007,34(1):86-90 [23] 邓娟,白洁. TRPC1和Ca2+在帕金森病内质网应激中的作用[J]. 生命科学,2012,24(10):1169-1173. [24] Gail D Zeevalk, Laura P Bernard. Energy status, ubiquitin proteasomal function, and oxidative stress during chronic and acute complex I inhibition with rotenone in mesencephalic cultures [J]. Antioxid Redox Signal, 2005, 7(5-6): 662-672. [25] Liu Ming-chao, Cai Tong-jian, Zhao Fang, et al. Effect of microglia activation on dopaminergic neuronal injury induced by manganese, and its possible mechanism[J]. Neurotox Res, 2009, 16(1): 42-49. [26] Verkhratsky A, Toescu E C. Neuronal-glial networks as substrate for CNS integration [J]. J Cell Mol Med, 2006, 10(4):826-836. [27] Mahmoud M Iravani, Clement C Leung, Mona Sadeghian, et al. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation[J]. Eur J Neurosci, 2005, 22(2): 317-330. [28] Toshi Nagatsu, Makoto Sawada. Cellular and molecular mechanisms of Parkinson's disease:neurotoxins, causative genes, and inflammatory cytokines[J]. Cell Mol Neurobiol, 2006, 26(4-6): 781-802. [29] W Michael Caudle, Zhang Jing. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease[J]. Exp Neurol, 2009, 220(2): 230-233. [30] Patrica A Trimmer, Trisha S Smith, Anthony B Jung, et al. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity[J]. Neurodegeneration, 1996, 5(3):233-239. [31] Oren A Levy, Cristina Malagelada, Lloyd A Greene. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps[J]. Apoptosis, 2009, 14(4): 478-500. [32] Karl Kieburtz, Bernard Ravina. Why hasn't neuroprotection worked in Parkinson's disease[J]. Nat Clin Pract Neurol, 2007, 3(5): 240-241. [33] Jorg B Schulz. Mechanisms of neurodegeneration in idiopathic Parkinson's disease[J]. Parkinsonism Relat Disord, 2007, 13 (Suppl 3): S306-S308. [34] Kaivalya J Vyas, John H Weiss. BMAA--an unusual cyanobacterial neurotoxin[J]. Amyotroph Lateral Scler, 2009, 10 (Suppl 2): 50-55. |
[1] | 何盼, 刘月涛, 杜冠华, 秦雪梅.肌少症研究进展[J]. 神经药理学报, 2020, 10(1): 47-53. |
[2] | 禹文峰,李成朋,韩飞,官志忠.硫辛酸抑制AIF 介导的非Caspase 凋亡通路对多巴胺能神经元的保护机制[J]. 神经药理学报, 2018, 8(2): 40-40. |
[3] | 高志红,左亚奇,张晓丽.黄芪甲苷诱导骨髓间充质干细胞治疗帕金森病的新思路[J]. 神经药理学报, 2017, 7(5): 39-44. |
[4] | 万叶,郭春燕,李永民.中药在帕金森病领域的研究进展[J]. 神经药理学报, 2017, 7(4): 36-42. |
[5] | 张丽娜,张欣,薛娟,张丹参.中药对中枢神经退行性疾病信号通路影响的研究进展[J]. 神经药理学报, 2017, 7(3): 33-42. |
[6] | 余汇,钟佳宏,钟秋萍,汪海涛,王文雅, 徐江平.Tideglusib 对MPP+ 诱导的SH-SY5Y 细胞凋亡的保护作用及其机制研究[J]. 神经药理学报, 2017, 7(2): 61-61. |
[7] | 钟佳宏,汪海涛,徐江平.α - 突触核蛋白与帕金森病[J]. 神经药理学报, 2017, 7(2): 62-62. |
[8] | 杨明艳,王冬雪,王玥,毕玉莹,毕田田.帕金森病轻度认知障碍[J]. 神经药理学报, 2017, 7(2): 63-63. |
[9] | 汪林芳,黄术兵,徐一达,崔春,申延琴.马钱苷对MPTP 诱导的PC12 细胞自噬的作用研究[J]. 神经药理学报, 2016, 6(5): 14-21. |
[10] | 张美金,王莎莎,张钊,陈乃宏,胡金凤.核转录因子Nrf2 在帕金森病中的作用[J]. 神经药理学报, 2016, 6(1): 35-40. |
[11] | 娄钰霞,张钊,王真真,姜懿纳,张毅,李林,陈乃宏.帕金森病相关基因DJ-1 与氧化应激[J]. 神经药理学报, 2016, 6(1): 58-64. |
[12] | 高杨,段冷昕.细胞自噬在帕金森病和阿尔茨海默病中的研究进展[J]. 神经药理学报, 2015, 5(3): 22-27. |
[13] | 郝军荣,沈丽霞.蛋白质组学在帕金森病研究中的应用研究进展[J]. 神经药理学报, 2015, 5(3): 28-35. |
[14] | 姜懿纳, 陈乃宏.帕金森病致病基因Parkin的研究进展[J]. 神经药理学报, 2015, 5(3): 36-45. |
[15] | 吴志刚,沈丽霞.帕金森病患者下尿路功能障碍的治疗进展[J]. 神经药理学报, 2014, 4(4): 36-41. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||